Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.

WHEN: Tuesday September 23rd at 11:25am (Local Time)

WHERE: Zurich, Switzerland

About Sachs Associates Biotech in Europe Investor Forum

-------------------------------------------------------

The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Sinovac Biotech Ltd. (Nasdaq: SVA), ... announced its unaudited financial results for the fourth quarter ... Fourth Quarter 2014 Financial Highlights(Compared to the fourth quarter ... a decrease of 11.4% from $22.9 million in the ... of H5N1 pandemic influenza vaccine of $0.1 million in ...
(Date:4/18/2015)... 18, 2015 Aurigene and ... will be presenting data at the poster sessions ... Cancer Research Annual Meeting (April 18-22 in ... (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene ... (NAMPT) small molecule inhibitors program, which is currently ...
(Date:4/17/2015)... TORONTO , April 17, 2015 /PRNewswire/ - SQI ... sciences and diagnostics company that develops and commercializes ... ("SQI"), today announced that it has received approval ... expiry of 5,126,044 outstanding common share purchase warrants ... in connection with the Company,s May 2013 private ...
(Date:4/17/2015)... LC Sciences LLC, a leading ... that it is seeking beta testers for the ... based targeted sequencing technology. The system offers cost-effective, ... accurate detection of rare variants. It utilizes novel ... company will collaborate with beta testers to generate ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3
... and non-profit SRI International have announced they are ... technologies. Company officials said the two organizations would ... sizes of technology companies. , ,"Companies with creative ... their concepts and bring them to successful commercialization," ...
... It's hard to argue about improvement. Motherhood, apple pie, the ... truths not apt to cause a fight after a ... choose to do things worse the next time. Einstein's theory ... head when he defined insanity as doing the same things ...
... Dumesic, graduate students Steven T. Evans, Tobias Voitl, Gabriel ... UW-Madison. MADISON - Carbon monoxide, or CO, has ... operation of fuel cells. But now, chemical and biological ... cleared that barrier - they also have discovered a ...
Cached Biology Technology:The Real World 2The Real World 3UW engineers clear bottleneck in hydrogen production 2
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... the launch of its newest journal, Cell Reports ... 2012. Cell Reports , the first open-access online-only journal ... life science spectrum. The journal will focus on shorter, single-point ... with all Cell Press journals, the primary criterion for both ...
... tuberculosis? Scientists may now be able to answer this question ... based on what they learn. That,s because new research presented ... ) suggests that two frequent mutations in an immune system ... make us less likely to resist the disease. ...
... scientific, technical and medical information products and services, introduces ... ScienceDirect for applicable life sciences journals. The Genome Viewer ... genomic sequence information on the genes mentioned in an ... browser developed by NCBI (the National Center for Biotechnology ...
Cached Biology News:Announcing Cell Reports -- a new open-access journal from Cell Press 2New discovery brings customized tuberculosis therapies based on genotype closer to reality 2Elsevier introduces Genome Viewer 2
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is ... to identify recombinant plasmids. ... X-Gal and IPTG, ... appear blue, whereas recombinant ...
Biology Products: